Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment

References

• Kwilas AR, Donahue RN, Bernstein MB, Hodge JW. In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front Oncol 2012; 2:104; http://dx.doi.org/10.3389/fonc.2012.00104; PMID: 22973551
   PubMedGoogle Scholar
• Lesokhin AM, Merghoub T, Wolchok JD. Myeloid-derived suppressor sells and the efficacy of CD8(+) T-cell immunotherapy. Oncoimmunology 2013; 2:e22764; http://dx.doi.org/10.4161/onci.22764; PMID: 23525353
   PubMed Web of Science ®Google Scholar
• Dannenmann SR, Thielicke J, Stöckli M, Matter C, von Boehmer L, Cecconi V, Hermanns T, Hefermehl L, Schraml P, Moch H, et al. Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology 2013; 2:e23562; http://dx.doi.org/10.4161/onci.23562; PMID: 23687622
   PubMed Web of Science ®Google Scholar
• Weiss VL, Lee TH, Jaffee EM, Armstrong TD. Targeting the right regulatory T-cell population for tumor immunotherapy. Oncoimmunology 2012; 1:1191 - 3; http://dx.doi.org/10.4161/onci.20664; PMID: 23170276
   PubMed Web of Science ®Google Scholar
• Ko HJ, Kim YJ, Kim YS, Chang WS, Ko SY, Chang SY, Sakaguchi S, Kang CY. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 2007; 67:7477 - 86; http://dx.doi.org/10.1158/0008-5472.CAN-06-4639; PMID: 17671218
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Sun J, Singhal S, Kapoor V, Cheng G, Suzuki E, Albelda SM. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther 2010; 18:1947 - 59; http://dx.doi.org/10.1038/mt.2010.159; PMID: 20683443
   PubMed Web of Science ®Google Scholar
• Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11:6713 - 21; http://dx.doi.org/10.1158/1078-0432.CCR-05-0883; PMID: 16166452
   PubMed Web of Science ®Google Scholar
• Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003; 63:4490 - 6; PMID: 12907622
   PubMed Web of Science ®Google Scholar
• Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38:729 - 41; http://dx.doi.org/10.1016/j.immuni.2013.03.003; PMID: 23562161
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51 - 72; http://dx.doi.org/10.1146/annurev-immunol-032712-100008; PMID: 23157435
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013; 2:e23510; http://dx.doi.org/10.4161/onci.23510; PMID: 23687621
   PubMed Web of Science ®Google Scholar
• Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29:482 - 91; http://dx.doi.org/10.1038/onc.2009.356; PMID: 19881547
   PubMed Web of Science ®Google Scholar
• Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, Nierkens S, Schreibelt G, de Boer A, Van Herpen CM, Kaanders JH, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 2011; 121:3100 - 8; http://dx.doi.org/10.1172/JCI43656; PMID: 21765211
   PubMed Web of Science ®Google Scholar
• Gonzalez-Aparicio M, Alzuguren P, Mauleon I, Medina-Echeverz J, Hervas-Stubbs S, Mancheno U, Berraondo P, Crettaz J, Gonzalez-Aseguinolaza G, Prieto J, et al. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice. Gut 2011; 60:341 - 9; http://dx.doi.org/10.1136/gut.2010.211722; PMID: 20855451
   PubMed Web of Science ®Google Scholar
• Bruchard M, Mignot G, Derangère V, Chalmin F, Chevriaux A, Végran F, Boireau W, Simon B, Ryffel B, Connat JL, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2013; 19:57 - 64; http://dx.doi.org/10.1038/nm.2999; PMID: 23202296
   PubMed Web of Science ®Google Scholar
• Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y, Zeng G, Wunderlich JR, Nguyen DM, Restifo NP, et al. De novo induction of a cancer/testis antigen by 5-aza-2′-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res 2006; 66:1105 - 13; http://dx.doi.org/10.1158/0008-5472.CAN-05-3020; PMID: 16424047
   PubMed Web of Science ®Google Scholar
• Umansky V, Sevko A. Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. Cancer Immunol Immunother 2012; 61:275 - 82; http://dx.doi.org/10.1007/s00262-011-1164-6; PMID: 22120757
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu N, Xiong SD, Zheng YJ, Chu YW. CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of toll-like receptor 4. Scand J Immunol 2011; 73:301 - 8; http://dx.doi.org/10.1111/j.1365-3083.2011.02514.x; PMID: 21223350
   PubMed Web of Science ®Google Scholar
• Zhong H, Han B, Tourkova IL, Lokshin A, Rosenbloom A, Shurin MR, Shurin GV. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin Cancer Res 2007; 13:5455 - 62; http://dx.doi.org/10.1158/1078-0432.CCR-07-0517; PMID: 17875775
   PubMed Web of Science ®Google Scholar
• Medina-Echeverz J, Fioravanti J, Zabala M, Ardaiz N, Prieto J, Berraondo P. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol 2011; 186:807 - 15; http://dx.doi.org/10.4049/jimmunol.1001483; PMID: 21148040
   PubMed Web of Science ®Google Scholar
• Medina-Echeverz J, Berraondo P. Colon cancer eradication after chemoimmunotherapy is associated with intratumoral emergence of proinflammatory myeloid cells. Oncoimmunology 2012; 1:118 - 20; http://dx.doi.org/10.4161/onci.1.1.18049; PMID: 22720230
   PubMed Web of Science ®Google Scholar
• Hirschhorn-Cymerman D, Rizzuto GA, Merghoub T, Cohen AD, Avogadri F, Lesokhin AM, Weinberg AD, Wolchok JD, Houghton AN. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med 2009; 206:1103 - 16; http://dx.doi.org/10.1084/jem.20082205; PMID: 19414558
   PubMed Web of Science ®Google Scholar
• Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 2012; 18:5329 - 40; http://dx.doi.org/10.1158/1078-0432.CCR-12-1632; PMID: 22850568
   PubMed Web of Science ®Google Scholar
• Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P, Scolyer RA. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012; 18:1386 - 94; http://dx.doi.org/10.1158/1078-0432.CCR-11-2479; PMID: 22156613
   PubMed Web of Science ®Google Scholar
• Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70:5213 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-10-0118; PMID: 20551059
   PubMed Web of Science ®Google Scholar
• Hannesdóttir L, Tymoszuk P, Parajuli N, Wasmer MH, Philipp S, Daschil N, Datta S, Koller JB, Tripp CH, Stoitzner P, et al. Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol 2013; http://dx.doi.org/10.1002/eji.201242505; PMID: 23843024
   PubMed Web of Science ®Google Scholar
• Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, Minasyan A, Graham NA, Graeber TG, Chodon T, et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 2012; 72:3928 - 37; http://dx.doi.org/10.1158/0008-5472.CAN-11-2837; PMID: 22693252
   PubMed Web of Science ®Google Scholar
• Rossig C. Immune modulation by molecular cancer targets and targeted therapies: Rationale for novel combination strategies. Oncoimmunology 2012; 1:358 - 60; http://dx.doi.org/10.4161/onci.18401; PMID: 22737614
   PubMed Web of Science ®Google Scholar
• Petrelli F, Cabiddu M, Cazzaniga ME, Cremonesi M, Barni S. Targeted therapies for the treatment of breast cancer in the post-trastuzumab era. Oncologist 2008; 13:373 - 81; http://dx.doi.org/10.1634/theoncologist.2007-0173; PMID: 18448551
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003; 170:6338 - 47; PMID: 12794167
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004; 64:4328 - 37; http://dx.doi.org/10.1158/0008-5472.CAN-04-0073; PMID: 15205348
   PubMed Web of Science ®Google Scholar
• Hodge JW, Sharp HJ, Gameiro SR. Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. Cancer Biother Radiopharm 2012; 27:12 - 22; http://dx.doi.org/10.1089/cbr.2012.1202; PMID: 22283603
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Gelbard A, Carrasquillo JA, Yu S, Mamede M, Paik CH, Camphausen K, Schlom J, Hodge JW. Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. Cancer Immunol Immunother 2008; 57:1173 - 83; http://dx.doi.org/10.1007/s00262-008-0449-x; PMID: 18256832
   PubMed Web of Science ®Google Scholar
• Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A, Yu P, Fu YX, Weichselbaum RR, Rowley DA, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 2007; 204:49 - 55; http://dx.doi.org/10.1084/jem.20062056; PMID: 17210731
   PubMed Web of Science ®Google Scholar
• Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009; 15:5379 - 88; http://dx.doi.org/10.1158/1078-0432.CCR-09-0265; PMID: 19706802
   PubMed Web of Science ®Google Scholar
• Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A, McLaughlin NM, Duret H, Yagita H, Johnstone RW, Smyth MJ, et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 2012; 72:3163 - 74; http://dx.doi.org/10.1158/0008-5472.CAN-12-0210; PMID: 22570253
   PubMed Web of Science ®Google Scholar
• Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010; 120:694 - 705; http://dx.doi.org/10.1172/JCI40283; PMID: 20179352
   PubMed Web of Science ®Google Scholar
• Aird WC. Endothelial cell heterogeneity. Cold Spring Harb Perspect Med 2012; 2:a006429; http://dx.doi.org/10.1101/cshperspect.a006429; PMID: 22315715
   PubMed Web of Science ®Google Scholar
• Ganss R, Ryschich E, Klar E, Arnold B, Hämmerling GJ. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 2002; 62:1462 - 70; PMID: 11888921
   PubMed Web of Science ®Google Scholar
• Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70:6171 - 80; http://dx.doi.org/10.1158/0008-5472.CAN-10-0153; PMID: 20631075
   PubMed Web of Science ®Google Scholar
• Palazón A, Teijeira A, Martínez-Forero I, Hervás-Stubbs S, Roncal C, Peñuelas I, Dubrot J, Morales-Kastresana A, Pérez-Gracia JL, Ochoa MC, et al. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res 2011; 71:801 - 11; http://dx.doi.org/10.1158/0008-5472.CAN-10-1733; PMID: 21266358
   PubMed Web of Science ®Google Scholar
• Manning EA, Ullman JG, Leatherman JM, Asquith JM, Hansen TR, Armstrong TD, Hicklin DJ, Jaffee EM, Emens LA. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res 2007; 13:3951 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-07-0374; PMID: 17606729
   PubMed Web of Science ®Google Scholar
• Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, Prell R, VanRoey MJ, Simmons AD, Jooss K. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res 2006; 12:6808 - 16; http://dx.doi.org/10.1158/1078-0432.CCR-06-1558; PMID: 17121902
   PubMed Web of Science ®Google Scholar
• Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010; 330:827 - 30; http://dx.doi.org/10.1126/science.1195300; PMID: 21051638
   PubMed Web of Science ®Google Scholar
• Molckovsky A, Siu LL. First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J Hematol Oncol 2008; 1:20; http://dx.doi.org/10.1186/1756-8722-1-20; PMID: 18959794
   PubMed Web of Science ®Google Scholar
• Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331:1612 - 6; http://dx.doi.org/10.1126/science.1198443; PMID: 21436454
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Sharkey RM. Using antibodies to target cancer therapeutics. Expert Opin Biol Ther 2012; 12:1173 - 90; http://dx.doi.org/10.1517/14712598.2012.693472; PMID: 22650606
   PubMed Web of Science ®Google Scholar
• Chi KH, Liu SJ, Li CP, Kuo HP, Wang YS, Chao Y, Hsieh SL. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother 2005; 28:129 - 35; http://dx.doi.org/10.1097/01.cji.0000154248.74383.5e; PMID: 15725956
   PubMed Web of Science ®Google Scholar
• Lechleider RJ, Arlen PM, Tsang KY, Steinberg SM, Yokokawa J, Cereda V, Camphausen K, Schlom J, Dahut WL, Gulley JL. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res 2008; 14:5284 - 91; http://dx.doi.org/10.1158/1078-0432.CCR-07-5162; PMID: 18698048
   PubMed Web of Science ®Google Scholar
• Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013; 24:1813 - 21; http://dx.doi.org/10.1093/annonc/mdt107; PMID: 23535954
   PubMed Web of Science ®Google Scholar
• Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203:1259 - 71; http://dx.doi.org/10.1084/jem.20052494; PMID: 16636135
   PubMed Web of Science ®Google Scholar